Positive opinion from Committee for Medicinal Products for Human Use (CHMP) based on Bylvay Phase III ASSERT clinical-trial data in…
Talquetamab is the first therapy targeting GPRC5D to receive a positive CHMP Opinion Teclistamab, the first BCMA-targeting bispecific antibody to…
Positive opinion from Committee for Medicinal Products for Human Use (CHMP) based on Bylvay Phase III ASSERT clinical-trial data in…
CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical, Inc. (“Nalu”), a Carlsbad, California-based neurostimulation company that has miniaturized neurostimulation implants for the management of…
Findings, Presented at Annual American Society of Pain & Neuroscience Conference, Demonstrate Significant and Durable Relief of Chronic Vertebrogenic Low…
Neurovations Research proud to be a part of study that released first positive results to slow Alzheimer's DiseaseNAPA, CA /…
Policy Updates Impact Nationwide Commercial Plans for 16.8 Million Covered LivesMALVERN, Pa., July 19, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc.…
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease Small molecule varoglutamstat,…
VANCOUVER, British Columbia, July 14, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or…
Dr. Adrienne Graves to join Board of DirectorsBEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a…